Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from HIMS

MarketBeat Week in Review – 03/03 - 03/07

Stocks had another down week despite a mostly benign jobs report; and with the latest reads on inflation coming next week the uncertainty may continue

MarketBeat

Surprising decision sends weight-loss drug stock reeling

The company has been riding a wave of demand for weight loss drugs.

The Street

Hims Stock Claws Back After Novo Nordisk Undercuts It With A Cheaper Wegovy

Novo Nordisk slashed the price of Wegovy by more than half on Wednesday amid a bitter rivalry with Hims & Hers Health.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Missed the Hims & Hers Rally? Clover Health Could Be Next

After a steep decline from its all-time high prices, shares of Hims & Hers are now recovering to show investor interest in the space.

MarketBeat

Behind Hims Stock's Roller-Coaster Ride As Weight-Loss Drugs Battle Heats Up

Hims & Hers Health put out a jaw dropping commercial. Now, Hims stock is just dropping, as its semaglutide business faces a setback.

Investors Business Daily

Hims & Hers Health Sparks Investors Interest with Unusual Options Trading

Hims and Hers Health produced sterling results on Feb. 24, spurring huge interest in HIMS call options trading. Barchart reported an unusual volume today in HIMS call options that expire on March 14.

Barchart

Wall Street’s Most Wanted: 2 Highly Shorted Stocks Right Now

See why these two high-flying stocks are among the most shorted in the market, plus counterarguments amid bearish gripes.

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

Dow Jones Futures Rise As Nvidia Partner Super Micro Soars; Tesla, Hims Lead Growth Woes

Futures rose as Nvidia partner Super Micro and Axon soared. Tesla and Hims dived Tuesday as growth stocks continue to struggle.

Investors Business Daily

Hims & Hers Stock Is Plunging on Weight-Loss Drug Halt. Should You Buy the Dip?

Concerns over near-term profit margins and the loss of potential revenue from compounded semaglutide weigh on Hims & Hers stock.

Barchart

Dow Jones Futures Rise: Trump Tariffs 'Going Forward;' Nvidia, Palantir Sell Off; Hims Plunges Late

Dow Jones Futures: President Trump's tariffs on Canada and Mexico are "going forward." Nvidia and Palantir tumbled Monday.

Investors Business Daily

Why IBD 50's Top Seed, Hims & Hers, Just Crashed On Its Upbeat Earnings

Hims stock plunged Tuesday after the compounding pharmacy issued a bullish outlook that still includes knockoff versions of semaglutide.

Investors Business Daily

MarketBeat Week in Review – 02/17 - 02/21

Stocks were volatile this week as bad news gave investors a reason to sell; that volatility will continue next week with key retail earnings and inflation news

MarketBeat

Hims Stock Crashes After FDA Resolves Weight-Loss Drugs Shortage

HIMS stock fell after the FDA said the shortages in Novo Nordisk's weight-loss drug has been resolved.

Investors Business Daily

Hims & Hers Earnings Could Be a Game Changer—What to Do Now

After a massive 500% run over the past 12 months, shares of Hims & Hers stock might have another trick saved up before earnings announcements.

MarketBeat

Get all your
news in one place.

100’s of premium titles.
One news app.

MarketBeat

Hims & Hers: From Viral Ad to Volatile Stock

Hims & Hers leverages its viral Super Bowl advertisement and strategic weight loss market entry to achieve stock gains and brand recognition in telehealth.

Investors Business Daily

Hims & Hers Option Trade Offers $410 Return Or 17% Discount

The goal is to either have the put expire worthless and keep the premium, or be assigned and acquire the stock below the current price.

MarketBeat

GLP-1 Alternatives: 2 Stocks Benefiting From Weight Loss Trends

GLP-1 weight loss drugs are in short supply enabling lab to make compounded GLP-1 treatments sold for 80% less than the name-brand drugs.

Investors Business Daily

IBD 50 Stock Hims & Hers Faces Backlash Over Provocative Super Bowl Ad

Hims stock surged Friday after facing backlash over its provocative Super Bowl ad.

Get all your
news in one place.

100’s of premium titles.
One news app.

MarketBeat

Hims & Hers Health: A Stock to Trade or Own?

HIMS achieved remarkable growth in 2024 but now faces challenges in 2025, raising the question of whether it suits traders better than long-term investors.

MarketBeat

Top Growth Picks: 3 Low-Cost Stocks That Could Double in Value

Here are three low-priced stocks you can buy today that are positioned in sector that make them solid choices to double in 2025

StockNews.com

3 Telemedicine Stocks Making Healthcare More Accessible

The telemedicine industry is transforming healthcare with digital platforms, growing consumer demand, and innovative care delivery models. As the sector evolves, telemedicine stocks like Doximity (DOCS), Hims & Hers Health (HIMS), and GoodRx Holdings (GDRX) are well-positioned to capitalize on this trend. Read on….

Investors Business Daily

IBD 50's Hims & Hers Tumbles After FDA Pulls Lilly's Weight-Loss Drug From Shortage List

Hims stock skidded Thursday after the FDA determined Eli Lilly's tirzepatide — which sells as a weight-loss drug — is no longer in shortage.

MarketBeat

4 Stocks That Crushed Analyst Estimates by More Than Double

Hims & Hers, Alcoa, Vicor, and Stride crushed earnings with massive EPS beats. See what’s driving their growth and future potential.

Benzinga

10 Health Care Stocks Whale Activity In Today's Session

This whale alert can help traders discover the next big trading opportunities.

MarketBeat

2 Telehealth Stocks That Could Gain from Trump’s New FDA Pick

Discover two telehealth stocks, Hims & Hers (HIMS) and Teladoc (TDOC), poised to benefit from Trump's FDA nominee, Dr. Marty Makary, a telemedicine advocate.

1 2 3

People

Gabriel OsorioMazilli

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.